Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Chiara Falcomatà receives Helmholtz Doctoral Award 2023

No. 38 | 17/07/2023 | by Koh

Can sophisticated combinations of cancer drugs improve treatment outcomes? Chiara Falcomatà made an outstanding discovery in this regard in her doctoral thesis at the Munich site of the German Cancer Consortium (DKTK). In mice, she developed a novel approach for a combination therapy against a highly aggressive form of pancreatic cancer that makes the tumor immunologically vulnerable. The Helmholtz Association honors this excellent achievement and has awarded Chiara Falcomatà the annual Doctoral Prize 2023 in the field of health.

Chiara Falcomatà
© private

With the doctoral awards, the Helmholtz Association annually honors young scientists in each of its six research fields who have carried out their doctoral studies at a Helmholtz center and completed them with outstanding results. Chiara Falcomatà, this year's award winner in the field of health, conducted research at the DKTK site at the Technical University of Munich (TUM) in Dieter Saur's laboratory. She receives the award for developing a novel combined therapeutic approach against a highly aggressive form of pancreatic cancer, mesenchymal pancreatic carcinoma. The cancer is resistant to all standard therapies available today, so even potent combination chemotherapies fail.

Immunotherapies are also usually unsuccessful, as pancreatic cancer is generally very difficult for immune cells to access. Chiara Falcomatà has found a way to make such immunologically "cold" pancreatic tumors amenable to immunotherapy by specifically combining two anticancer drugs in an animal model in mice.

In an extensive screening of more than 400 therapeutic agents, Chiara Falcomatà discovered two drugs that enhance each other's effect and lead to cell death of the cancer cells. Using the CRISPR gene scissors, the biologist examined in detail which molecular processes are influenced by the drug combination in patient cells and in mice. In the process, she found that T cells are better able to enter the tumor under the combination therapy.

This observation led the researcher to the idea of supplementing the combination therapy with the administration of immune checkpoint inhibitors, which boost the immune defense against cancer. This triple treatment significantly improved tumor response. Mice carrying the highly aggressive mesenchymal subtype of pancreatic cancer showed a clear survival benefit with the triple therapy. If the result obtained in the animal model can be translated to humans, it could represent, for the first time, a potential treatment option for those affected by the disease, which could potentially prove effective in other tumor types as well.

Chiara Falcomatà studied molecular biotechnology in Turin. After completing her PhD, she initially conducted postdoctoral research in Dieter Saur's lab and recently moved to the Icahn School of Medicine at Mount Sinai Hospital in New York, where she is continuing her work on pancreatic cancer.

Award winners receive prize money of 5,000 euros, plus a travel and material grant for a research stay abroad of up to 12,000 euros.

A picture of Chiara Falcomatà is available for download: 

Note on use of images related to press releases
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: "Source: private".
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ's Press Office (phone: ++49-(0)6221 42 2854, E-mail: Any commercial use is prohibited.

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS